Overview

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2030-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Phase:
PHASE3
Details
Lead Sponsor:
Keymed Biosciences Co.Ltd
Treatments:
Standard of Care